Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858311 | 0.88 | MAPT (0.45) | KDM4EALDH1A1MAPTEDNRBMAPK8 | |
| SCHEMBL6858294 | 0.81 | MAPK8 (0.46) | KDM4EALDH1A1MAPTEDNRBMAPK8 | |
| SCHEMBL6856133 | 0.79 | EDNRB (0.47) | KDM4EALDH1A1MAPTEDNRBMAPK8 | |
| SCHEMBL6858324 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1MAPTEDNRBMAPK8 | |
| SCHEMBL6859416 | 0.76 | EDNRB (0.45) | KDM4EALDH1A1MAPTEDNRBMAPK8 | |
| SCHEMBL6856142 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1MAPTEDNRBMAPK8 | |
| SCHEMBL6858332 | 0.71 | PPARG (0.50) | KDM4EMAPTEDNRBMAPK8KMT2A | |
| SCHEMBL6858280 | 0.71 | PLA2G2A (0.53) | EDNRBMAPK8KMT2APLA2G2A | |
| SCHEMBL6851276 | 0.70 | EDNRB (0.52) | MAPTEDNRBMAPK8KMT2APPARG | |
| SCHEMBL6851257 | 0.70 | PLA2G2A (0.53) | MAPTEDNRBMAPK8KMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | KDM4E 1858/4885ALDH1A1 2691/4885MAPT 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.